One 1.5ml dose per horse to be administered by deep intramuscular injection. Shake well before use.

A single dose of Duvaxyn IE‑T Plus should be administered from the age of 5 months followed by a second dose of Duvaxyn IE‑T Plus after an interval of 4–6 weeks and a third dose 6 months later.

Primary vaccination of foals born to mares highly immunised against equine influenza or tetanus (i.e. vaccinated two or more times a year or within the last trimester of pregnancy) should be delayed until the age of 6 months, as such foals may have high levels of maternally-derived antibody against equine influenza virus and tetanus toxoid that could interfere with successful immunisation.

In cases of increased risk of equine influenza or tetanus in the young foal, especially when colostrum intake has been inadequate, an additional vaccination may be given from three months of age. Such foals should be shown to have no or very low titres of IgG using a suitable test before proceeding with early vaccination.

The full primary course of vaccination should still be given from five months of age.

Administer a single dose of vaccine annually, beginning with Duvaxyn IE Plus and alternating thereafter with Duvaxyn IE-T Plus.

In enzootic or epizootic situations, especially where the causative strain of equine influenza has not been identified, young horses in a yard or crowded situation may be particularly at risk and an additional 6 month booster with Duvaxyn IE Plus may be given in order to further enhance the immune response prior to the commencement of the annual booster programme.

It is recommended that Duvaxyn IE-T Plus should not be used as a booster vaccine in horses previously vaccinated with another manufacturer's vaccine nor should another manufacturer's vaccine be used as a booster vaccine in horses previously vaccinated with Duvaxyn IE-T Plus unless the other manufacturer's vaccine comprises the same equine influenza strains as Duvaxyn IE-T Plus.